Dova Pharmaceuticals is a clinical-stage pharmaceutical company focused on acquiring, developing, and marketing treatments for thrombocytopenia, a disorder characterized by a low blood platelet count. The Company's major drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist.

Dova has recently completed two identically designed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease, or CLD, undergoing non-emergent minimally to moderately invasive medical procedures.

Type
Public
HQ
Durham, US
Founded
2016
Size (employees)
7 (est)
Website
dova.com
Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, US
Report incorrect company information

Dova Pharmaceuticals Office Locations

Dova Pharmaceuticals has an office in Durham
Durham, US (HQ)
245 240 Leigh Farm Rd
Show all (1)
Report incorrect company information

Dova Pharmaceuticals Financials and Metrics

Dova Pharmaceuticals Financials

USD

Net income (FY, 2016)

(27.2 m)

EBIT (FY, 2016)

(27 m)

Market capitalization (22-Jun-2018)

897.9 m

Closing share price (22-Jun-2018)

31.9

Cash (31-Dec-2016)

28.7 m

EV

882.8 m
Dova Pharmaceuticals's current market capitalization is $897.9 m.
USDFY, 2016

General and administrative expense

1.2 m

R&D expense

25.8 m

Operating expense total

27 m

EBIT

(27 m)
USDFY, 2016

Cash

28.7 m

Current Assets

28.7 m

Total Assets

28.7 m

Accounts Payable

157 k
USDFY, 2016

Net Income

(27.2 m)

Accounts Payable

157 k

Cash From Operating Activities

(987 k)

Cash From Financing Activities

29.7 m
USDY, 2016

EV/EBIT

-32.6 x

EV/CFO

-894.5 x

Debt/Equity

2 x

Debt/Assets

0.5 x

Financial Leverage

4.2 x
Show all financial metrics

Dova Pharmaceuticals Operating Metrics

Mar, 2017Jun, 2017

Patents (foreign)

24

Patents Licensed

43

Patents Pending (foreign)

2

Phase III Trials Products

1
Show all operating metrics
Report incorrect company information